Edesa Biotech: paridiprubart shows 32% relative mortality reduction in AKI/ARDS patients

Edesa Biotech, Inc.

Exploratory Phase 3 data: paridiprubart + SOC reduced 28-day mortality to 33% vs 49% placebo (p<0.005).
MAKE30 composite endpoint incidence reduced to 41% from 53% (23% relative reduction, p<0.005).
AKI cohort of 101 severely ill patients (90% moderate-to-severe ARDS, ~50% on ventilation/ECMO).
Paridiprubart well tolerated; no significant differences in adverse events vs placebo.
Data presented at ERA Congress 2026; results exploratory and require confirmatory studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.